Multimodal Treatment Eliminates Cancer Stem Cells and Leads to Long-Term Survival in Primary Human Pancreatic Cancer Tissue Xenografts (Q28534130)

Annette Bakker

10

0 references

Patrick C. Hermann

Patrick C Hermann

1

0 references

Stephan Hahn

Stephan A Hahn

6

0 references

Manuel Hidalgo

Manuel Hidalgo

11

0 references

Christopher Heeschen

12

Christopher Heeschen

0 references

Bruno Sainz

Bruno Sainz

3

1 reference

ORCID Public Data File 2021

author name string

Sara M Trabulo

2

0 references

Elena Garcia

5

0 references

Mallaredy Vandana

7

0 references

Sanjeeb K Sahoo

8

0 references

Patrizia Tunici

Creative Commons Attribution 4.0 International

9

0 references

language of work or name

English

0 references

publication date

2013

0 references

published in

PLOS One

0 references

volume

8

0 references

issue

6

0 references

page(s)

e66371

0 references

copyright license

start time

18 June 2013

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

The crosstalk of mTOR/S6K1 and Hedgehog pathways

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3688976

19 March 2017

Cancer statistics, 2010

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3688976

Core signaling pathways in human pancreatic cancers revealed by global genomic analyses

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3688976

Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3688976

Identification of pancreatic cancer stem cells

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3688976

Glioma stem cells promote radioresistance by preferential activation of the DNA damage response

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3688976

Stem cells, cancer, and cancer stem cells

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3688976

FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3688976

Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3688976

Pancreatic stellate cells form a niche for cancer stem cells and promote their self-renewal and invasiveness.

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3688976

Drugs in preclinical and early-stage clinical development for pancreatic cancer.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3688976

In vitro and in vivo characterization of a novel Hedgehog signaling antagonist in human glioblastoma cell lines.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3688976

Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3688976

Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3688976

Inhibition of ataxia telangiectasia- and Rad3-related function abrogates the in vitro and in vivo tumorigenicity of human colon cancer cells through depletion of the CD133(+) tumor-initiating cell fraction

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3688976

Long circulation and cytotoxicity of PEGylated gemcitabine and its potential for the treatment of pancreatic cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3688976

Pancreatic cancer stem cells - update and future perspectives.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3688976

Cancer stem cells in solid tumors.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3688976

Consensus report of the national cancer institute clinical trials planning meeting on pancreas cancer treatment.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3688976

Combined targeted treatment to eliminate tumorigenic cancer stem cells in human pancreatic cancer.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3688976

In vivo activity of gemcitabine-loaded PEGylated small unilamellar liposomes against pancreatic cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3688976

A direct pancreatic cancer xenograft model as a platform for cancer stem cell therapeutic development.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3688976

Gemcitabine combined with continuous infusion 5-fluorouracil in advanced and symptomatic pancreatic cancer: a clinical benefit-oriented phase II study

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3688976

Nodal/Activin signaling drives self-renewal and tumorigenicity of pancreatic cancer stem cells and provides a target for combined drug therapy.

29 September 2017

1 reference

Crossref

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0066371

Inhibition of the mammalian target of rapamycin impedes lymphangiogenesis

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23825539

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

c-Met is a marker of pancreatic cancer stem cells and therapeutic target

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23825539

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23825539

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1371/JOURNAL.PONE.0066371

1 reference

ADS bibcode

2013PLoSO...866371H

0 references

1 reference

1 reference

PubMed publication ID

23825539

1 reference